Acura Pharmaceuticals Inc. has announced plans for a new clinical study involving their drug candidate LTX-03, a formulation combining hydrocodone bitartrate and acetaminophen. This decision follows a recent meeting with the US Food and Drug Administration (FDA), where further development requirements were discussed. The study, designated AP-LTX-310, will compare a single tablet dose of LTX-03 to a single FDA Reference Standard drug under fed and fasted conditions. LTX-03 utilizes Acura's LIMITx technology, designed to lower peak drug blood concentrations as additional tablets are consumed. FDA has agreed to potentially describe the unique pharmacokinetic characteristics of LTX-03 in its labeling, subject to a New Drug Application (NDA) review. Acura Pharmaceuticals is also considering plans to support lower dosage strengths of LTX-03 for the NDA submission or after approval.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。